Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Data sourced from

and

Download Data

Freeline Therapeutics Holdings Plc Net Operating Profit After Tax (NOPAT) 5 year CAGR for the Trailing 12 Months (TTM) ending September 30, 2023: 2.99%

Freeline Therapeutics Holdings Plc Net Operating Profit After Tax (NOPAT) 5 year CAGR is 2.99% for the Trailing 12 Months (TTM) ending September 30, 2023. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Freeline Therapeutics Holdings Plc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending September 30, 2022 was -26,759,326.33, a 19.11% change year over year.
Freeline Therapeutics Holdings Plc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending September 30, 2021 was -33,081,827.10, a -86.63% change year over year.
Freeline Therapeutics Holdings Plc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending September 30, 2020 was -17,726,152.27, a -58.22% change year over year.
Freeline Therapeutics Holdings Plc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending March 31, 2019 was -11,203,515.41, a -11.91% change year over year.

NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO	Mr. Michael J. Parini J.D.
IPO Date	Aug. 7, 2020
Location	United Kingdom
Headquarters	Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees	152
Sector	Healthcare
Industry	Biotechnology

Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Key trends